The present invention relates to a method of inhibiting or reducing theproliferation of prostate cancer cells, such as androgen independent prostatecancer (AIPC) cells, the method comprising administering to the cells a PLA2inhibitor. In one embodiment the PLA2 inhibitor is a conformationallyconstrained molecule derived from a peptide consisting essentially of aminoacid residues 70-74 of a human sPLA2-IIA protein, or the equivalent residuesin other sPLA2 proteins.